FIP1L1 anticorps

N° du produit ABIN7263123

Cet anticorps anti-FIP1L1 est un anticorps Lapin Polyclonal détectant FIP1L1 dans WB, IHC et IF. Adapté pour Humain, Souris et Rat.

Aperçu rapide pour FIP1L1 anticorps (ABIN7263123)

Antigène: FIP1L1 (FIP1 Like 1 (FIP1L1))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FIP1L1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Détail du produit anti-FIP1L1 anticorps

Attributs du produit: Polyclonal Antibody

Purification: Affinity purification

Immunogène: Recombinant fusion protein of human FIP1L1 (NP_001128409.1).

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000 IHC 1:50-1:200 IF 1:50-1:100

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur FIP1L1

Antigène: FIP1L1 (FIP1 Like 1 (FIP1L1))

Autre désignation: FIP1L1

Sujet: This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Poids moléculaire:

Observed_MW: 80 kDa

Calculated_MW: 40 kDa/58 kDa/65 kDa/66 kDa

ID gène: 81608

UniProt: Q6UN15